Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Loxapine succinate (Loxapac), a D2DR and D4DR inhibitor, is utilized in schizophrenia.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
50 mg | 在庫あり | ¥ 7,500 | |||
100 mg | 在庫あり | ¥ 11,000 | |||
200 mg | 在庫あり | ¥ 17,500 | |||
500 mg | 在庫あり | ¥ 38,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 12,000 |
説明 | Loxapine succinate (Loxapac), a D2DR and D4DR inhibitor, is utilized in schizophrenia. |
ターゲット&IC50 | D2 receptor (human):24 nM(Ki), 5-HT2 (human):6.2 nM(Ki), 5-HT2 (bovine):6.6 nM(Ki), 5-HT2 (bovine):6.8 nM(Ki), D4 receptor (human):7.5 nM(Ki) |
In vitro | In rats, subcutaneous injection of Loxapine (0.3 mg/kg) induces general stiffness. In the rat brain, administering Loxapine (5 mg/kg) does not alter dopamine receptor density, but it reduces serotonin receptor density. |
In vivo | Loxapine effectively facilitates the binding of [3H]ketanserin to 5-HT2 receptors in both the human frontal cortex (ki=6.2 nM) and the bovine frontal cortex (ki=6.6 nM). Additionally, in LPS-activated mixed glial cells, loxapine at concentrations of 0.2 μM, 2 μM, and 20 μM, successfully reduces the secretion of IL-1β and IL-2. |
別名 | Daxolin, Loxapac, Cloxazepin, Loxapine succinate salt |
分子量 | 445.9 |
分子式 | C22H24ClN3O5 |
CAS No. | 27833-64-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 2 mg/mL (4.48 mM)
DMSO: 82 mg/mL (183.9 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Loxapine succinate 27833-64-3 GPCR/G Protein Neuroscience Dopamine Receptor 5-HT Receptor Daxolin antipsychotics Loxapac 5-hydroxytryptamine Receptor Loxapine serotonin Cloxazepin Serotonin Receptor Inhibitor inhibit schizophrenia IL-2 Loxapine succinate salt Loxapine Succinate IL-1β inhibitor